Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

towards enhanced recanalization of the occluded artery in treated subjects versus controls."

Following a comprehensive review of this program and taking into consideration the challenging financial market conditions, ImaRx's Board of Directors and management concluded that it is in the best interests of the Company and its shareholders to actively seek strategic alternatives for the funding and future development of its SonoLysis technology.

"Based on the encouraging results that were demonstrated in the first cohort of our TUCSON study, we believe that our SonoLysis technology remains an attractive development opportunity in ischemic stroke", stated Bradford A. Zakes. "We are actively evaluating options that will secure funding for the development of this technology while preserving the opportunity for our shareholders to realize significant value from our SonoLysis program."

Urokinase Business Update

Urokinase, the Company's first FDA-approved commercially available product is indicated for the treatment of acute massive pulmonary embolism. Formerly marketed as Abbokinase(R), the FDA approved ImaRx's request to market the product under a new trade name, Kinlytic. The Company acquired urokinase and all related assets, including an approximate four-year supply of inventory, from Abbott Laboratories (NYSE: ABT) in April 2006.

The Company commenced sales of urokinase in October 2006 and experienced consistent hospital pull-through in 2007. In order to continue selling product, the Company has maintained an ongoing stability testing program to support extending the expiration dating of the urokinase inventory. In October 2007, results from the stability testing program successfully met all of the required specifica
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... - Researchers are making progress in creating digital transistors ... thought to dramatically limit the material,s use in computers ... of carbon that conducts electricity with little resistance or ... earned a Nobel Prize in physics - it was ...
... was named by FierceBiotech today as one of 2011,s ... promising private biotechnology companies in the industry. This is FierceBiotech,s ... has done a super job of raising the funds and ... combination therapy – toward the market," says Ryan McBride, the ...
... Wash. and VANCOUVER, British Columbia, Sept. 6, 2011 ... today that data from two studies, a Phase II ... compound custirsen (OGX-011/TV-1011), were published in the September issues ... Cancer Research . Custirsen inhibits ...
Cached Biology Technology:Innovation is step toward digital graphene transistors 2FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech 2FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech 3OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 2OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 3OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 4OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 5
(Date:9/18/2014)... of carbon and nitrogen comprise all spheres of ... systems have caused imbalances and perturbations that resulted ... Increased GHGs result in climate changes which influence ... and the atmosphere. Understanding these feedback mechanisms has ... environmental science during the past three decades. , ...
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
(Date:9/18/2014)... is probably the ultimate form of camouflage: you don,t ... this strategy is not as uncommon as you might ... County, USA, explains that the larval life stages of ... part of the anatomy that most creatures cannot make ... have to shield each individual eye unit with an ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2
... Bethesda, MD This FASEB Science Research Conference ... of intestinal lipid digestion and absorption with new ... to understanding the mechanisms of health maintenance and ... resistance and diabetes, dyslipidemia, intestinal failure and gastrointestinal ...
... Conference focuses on recent advances in the methods for ... to promote the discovery and exchange of new methods ... facilitate the application of methods in protein structure analysis ... to support and foster the education of researchers in ...
... from Iowa State University (USA) published a study which ... metals. Now, a team from the University of the ... results throw this discovery into question. This has reaffirmed ... validity in the press. The resistance and elasticity ...
Cached Biology News:Spider silk ties scientists up in knots 2
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: